2024 EULAR congress research links anti-Ro/SSA antibodies to lung fibrosis and lower diffusion capacity in Systemic Sclerosis patients, potentially improving risk stratification.

2024 EULAR congress research reveals that anti-Ro/SSA antibodies are associated with lung fibrosis and lower diffusion capacity of carbon monoxide in Systemic Sclerosis (SSc) patients. Patients with anti-SSA antibodies have a higher risk of ILD and show more muscular involvement. The inclusion of anti-SSA antibodies in routine clinical practice could improve risk stratification for SSc patients. Recent changes in treatment patterns for SSc-ILD patients have reduced progressive ILD events, with progression-free survival at 45% at 3 years.